Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-alpha2a effects on complement activation and regulation in MS patients.

K M Myhr1, S Sadallah, T E Mollnes

  • 1Department of Neurology, Haukeland University Hospital, University of Bergen, Norway.

Acta Neurologica Scandinavica
|February 5, 2000
PubMed
Summary

Recombinant interferon-alpha2a (rIFN-alpha2a) treatment in multiple sclerosis (MS) patients initially activates complement, indicated by increased terminal complement complex (TCC) and C3bc levels. This may be linked to a decrease in complement receptor 1 (CR1/CD35).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis.

Multiple sclerosis and related disorders·2024
Same author

Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.

Journal of neurology·2023
Same author

Limbic Encephalitis following Allogeneic Hematopoietic Stem Cell Transplantation.

Case reports in immunology·2022
Same author

Lipopolysaccharides and outer membrane proteins as main structures involved in complement evasion strategies of non-typhoidal Salmonella strains.

Molecular immunology·2022
Same author

Complement activation and blockade in massive post-partum haemorrhage, thrombotic microangiopathy and acute kidney injury: a case report.

BMC nephrology·2021
Same author

Enhanced influenza A H1N1 T cell epitope recognition and cross-reactivity to protein-O-mannosyltransferase 1 in Pandemrix-associated narcolepsy type 1.

Nature communications·2021

Area of Science:

  • Immunology
  • Neuroimmunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
  • Interferon-alpha2a (IFN-alpha2a) is used in MS treatment, but its effects on the complement system are not fully understood.
  • The complement system plays a role in immune responses and inflammation.

Purpose of the Study:

  • To investigate the impact of recombinant interferon-alpha2a (rIFN-alpha2a) on complement activation and regulation in patients with multiple sclerosis (MS).

Main Methods:

  • Plasma levels of complement activation products (C3bc, TCC) and serum levels of complement regulatory proteins (CR1/CD35, CD59) were measured using ELISA.
  • MS patients received either rIFN-alpha2a (n=14) or placebo (n=7).
  • Leukocyte counts were also monitored.

Related Experiment Videos

Main Results:

  • In rIFN-alpha2a treated patients, soluble CR1/CD35 levels decreased.
  • Terminal complement complex (TCC) and C3bc levels increased during the initial phase of rIFN-alpha2a treatment.
  • A concurrent reduction in leukocyte counts was observed in the treated group.

Conclusions:

  • The findings suggest that rIFN-alpha2a treatment initiates complement activation in MS patients.
  • This initial complement activation may be associated with the observed decrease in soluble CR1/CD35.
  • Further research is needed to elucidate the precise mechanisms and clinical implications.